ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2555

Development and Validation Of a Questionnaire To Screen For The Presence Of Autoimmune Disease

Alan Boroway1, Aileen M. Davis2, Carolina Landolt-Marticorena1 and Joan E. Wither3, 1Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, 2Toronto Western Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, 31E420/Div of Rheumatology, Toronto Western Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: autoimmune diseases, family studies and questionnaires

  • Tweet
  • Email
  • Print
Session Information

Session Title: Systemic Lupus Erythematosus-Clinical Aspects III: Biomarkers, Quality of Life and Disease Indicators, Late Complications

Session Type: Abstract Submissions (ACR)

Background/Purpose:   Healthy family members of patients with systemic autoimmune rheumatic diseases (SARDs) are at higher risk of developing autoimmune disease than the general population.  It is postulated that serological changes precede the onset of clinical autoimmune disease in affected individuals.  Our aim is to determine if these serological changes are present in the relatives of patients with SARD, and if so, whether they can be used to predict the development of  autoimmune disease.  This would permit introduction of treatment early in the disease course thereby preventing damage.  We have previously obtained blood for serologic testing and performed a cellular analysis on the first-degree relatives of patients with systemic lupus erythematosus.  At the time of blood draw, a questionnaire was administered seeking evidence of autoimmune disease.  In total 893 medical histories were obtained via questionnaire, with 178 reporting an autoimmune disease.   However, less than 50% were able to be confirmed as accurate (Cooper et al, J Rheumatol. 2008 35 (10): 2001-4).  In this study, we developed a validated questionnaire that more accurately reflects the presence of autoimmune disease, that can be used for a follow-up of the first-degree relatives of patients with SARDs.

Methods:   A questionnaire was developed in consultation with an expert for distribution to patients for validation.  In contrast to our previous questionnaire it incorporates questions that have been developed to confirm the presence of disease through questions regarding specific clinical manifestions of disease and/or treatment.  After obtaining informed consent, the questionnaire was administered to patients with each autoimmune disease of interest, with those having other autoimmune diseases or osteoarthritis serving as controls.  Accuracy at identifying the presence or absence of a particular autoimmune disease was confirmed against data from patients’ medical records.  False positive (FP) and false negative (FN) rates were compared for each autoimmune disease.

Results:   63 patients were consented and completed the questionnaire, including at least 5 patients with each autoimmune disease of interest.   Results are shown below:

Comparison of Accuracy of Original Questionnaire (Cooper et al) and New Questionnaire

Cooper et al Questionnaire FP Rate

N (%)

 Questionnaire FP Rate (Screening Question)

N (%)

Questionnaire FP Rate (Confirmatory Questions)

N (%)

Questionnaire FN Rate (Confirmatory Questions)

N (%)

Systemic Lupus Erythematosus

9/24 (32.5%)

0/18 (0%)

—

—

Rheumatoid Arthritis

45/60 (75%)

6/12 (50%)

1/12 (8.3%)

—

Systemic Sclerosis

1/4 (25%)

0/13 (0%)

—

—

Polymyositis/Dermatomyositis

2/2 (100%)

6/10 (60%)

1/10 (10%)

—

Sjogren’s Syndrome

3/9 (33.3%)

3/9 (33.3%)

1/9 (11.1%)

—

Antiphospholipid Syndrome

4/5 (80%)

2/5 (40%)

1/5 (20%)

—

Hemolytic Anemia

12/13 (92.3%)

2/7 (28.6%)

2/7 (28.6%)

4/56 (7.1%)

Multiple Sclerosis

2/4 (50%)

1/6 (16.7%)

1/6 (16.7%)

1/57 (1.8%)

Thyroid Disease

45/96 (46.9%)

5/12 (41.7%)

0/12 (0%)

—

Type 1 Diabetes

N/A

0/10 (0%)

—

—

Idiopathic Thrombocytopenic Purpura

N/A

3/7 (43%)

1/7 (14.3%)

1/56 (1.8%)

There were no FP results in the general screening questions of both SLE and Type 1 DM.  In those SARDs that had FP responses to the original screening question, accuracy was was improved in many by the confirmatory questions.  In general FN rates were low.

Conclusion:   The new questionnaire improved overall accuracy over our original questionniare in screening for most autoimmune diseases and can be used to more accurately identify family members with these conditions.


Disclosure:

A. Boroway,
None;

A. M. Davis,
None;

C. Landolt-Marticorena,
None;

J. E. Wither,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-and-validation-of-a-questionnaire-to-screen-for-the-presence-of-autoimmune-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies